VANCOUVER, BC, June 24, 2024 /PRNewswire/ – The first patient has entered the Phase II/III trial of ST-02, Sustained Therapeutic’s innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC). A rare form of cancer, UTUC affects over 7,000 individuals annually across North…